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BIN1 is the second-most-prevalent
genetic risk factor for late-onset
Alzheimer’s disease. However, how BIN1
affects the disease remained largely
unknown. Using in vitro microcircuits,
Calafate et al. show that Tau aggregates
hijack endocytic routes to propagate and
find that BIN1 directly affects this process
by modulating the endocytic flux in
receiving neurons.
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Tau pathology propagates within synaptically con-
nected neuronal circuits, but the underlying mecha-
nisms are unclear. BIN1-amphiphysin2 is the second
most prevalent genetic risk factor for late-onset Alz-
heimer’s disease. Indiseasedbrains, theBIN1-amphi-
physin2 neuronal isoform is downregulated. Here, we
show that lowering BIN1-amphiphysin2 levels in neu-
rons promotes Tau pathology propagation whereas
overexpression of neuronal BIN1-amphiphysin2 in-
hibits the process in two in vitro models. Increased
Tau propagation is caused by increased endocytosis,
given our finding that BIN1-amphiphysin2 negatively
regulates endocytic flux. Furthermore, blocking endo-
cytosisby inhibitingdynaminalso reducesTaupathol-
ogy propagation. Using a galectin-3-binding assay,
we show that internalized Tau aggregates damage
the endosomal membrane, allowing internalized ag-
gregates to leak into the cytoplasm to propagate pa-
thology.Ourwork indicates that lowerBIN1 levelspro-
mote the propagation of Tau pathology by efficiently
increasing aggregate internalization by endocytosis
and endosomal trafficking.
INTRODUCTION
In Alzheimer’s disease (AD), Tau pathology progresses in a
temporospatial pattern throughout connected brain structures,
involving inter-neuronal propagation of abnormal Tau species
(Braak and Braak, 1991). This process contributes to AD patho-
genesis, and therefore, the mechanisms involved in the release
and uptake of pathogenic Tau species are potential therapeutic
strategies. However, the underlying mechanisms are not entirely
resolved and a link to AD pathogenesis is lacking.
One way of internalization of Tau aggregates has been sug-
gested to occur through endocytic routes (Frost et al., 2009;
Holmes et al., 2013; Santa-Maria et al., 2012; Wu et al., 2013).
The importance of membrane trafficking in AD pathogenesis is
highlighted by the discovery of several genes that increase
late-onset AD (LOAD) risk, including BIN1, PICALM, CD2AP,Ce
This is an open access article under the CC BY-NCD33, EPHA, RIN3, MEF2C, and PTK2B (Harold et al., 2009;
Karch and Goate, 2015; Lambert and Amouyel, 2011; Lambert
et al., 2013; Morgan, 2011; Seshadri et al., 2010). BIN1 is the
second-most-prevalent LOAD susceptibility genetic locus after
APOE, and the protein has a similar domain structure to amphi-
physin1 that is strongly implicated in synaptic vesicle endocy-
tosis (Wigge et al., 1997).
The BIN1 gene undergoes extensive tissue-specific alterna-
tive splicing, generating several isoformswith different functions.
In humans, isoforms 1–7 are specifically expressed in the brain,
isoform 8 in skeletal muscles, and isoforms 9 and 10 are ubiqui-
tous (Butler et al., 1997; Ellis et al., 2012; Prokic et al., 2014;
Ramjaun andMcPherson, 1998; Shupliakov et al., 1997; Wechs-
ler-Reya et al., 1997; Wigge et al., 1997). All isoforms induce or
sense membrane curvature via the BAR domain and bind dyna-
min through the SH3 domain. However, only the neuronal iso-
forms contain a CLAP domain that mediates the interaction to
clathrin and AP2, suggesting a specific role of BIN1 in clathrin-
mediated endocytosis (CME) in the brain (Micheva et al., 1997;
Ramjaun and McPherson, 1998; Slepnev et al., 2000; Wigge
et al., 1997). This is interesting because, despite the fact that to-
tal BIN1 mRNA levels were found increased in AD brains (Cha-
puis et al., 2013), the protein levels of the neuronal-specific
BIN1 isoform 1 were decreased whereas the levels of the ubiqui-
tous isoform 9 were increased (Holler et al., 2014). How neuronal
BIN1 controls CME and how the protein modulates the propaga-
tion of Tau pathology remain, however, enigmatic.
Using two in vitro models, we show that a neuronal BIN1, but
not a ubiquitous splice variant, inhibits the propagation of Tau
pathology. Conversely, the loss of BIN1 function promotes Tau
pathology propagation. We find that BIN1 is a negative regulator
of endocytosis in neurons and provide evidence that, when BIN1
is downregulated, the endosomal small guanosine triphospha-
tase (GTPase) Rab5 is over-activated. Consequently, the loss
of BIN1 increases the flux to endosomes, and our data suggest
that internalized Tau aggregates accumulate in these organelles.
Using a galectin-3-binding assay, we provide evidence that the
membranes of sub-cellular compartments with Tau aggregates
become damaged. This indicates that one mechanism of propa-
gation of pathology is that Tau leaks into the cytoplasm, where it
may seed further Tau pathology. We suggest that lower neuronal
BIN1 levels promote the propagation of Tau pathology by over-
activating Rab5 and increasing endocytic flux.ll Reports 17, 931–940, October 18, 2016 ª 2016 The Authors. 931
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
RESULTS
Rat Neurons in Culture only Express Neuronal BIN1
We first determined which isoforms are expressed in rat neu-
rons in culture. Whereas in humans at least ten BIN1 isoforms
were described, three isoforms have been described in rat
(Ensemble): a ubiquitous isoform (ENSRNOT00000049898); a
neuron-specific (ENSRNOT00000017573); and a skeletal-mus-
cle-specific (ENSRNOT00000042287) isoform equivalent to
human isoforms 9, 1, and 10, respectively. In total rat brain,
both the ubiquitous and the neuron-specific isoforms are de-
tected by western blot analysis, with the latter appearing as a
doublet due to phosphorylation (Ramjaun et al., 1997). Interest-
ingly, using synaptosome preparations, we find that the ubiqui-
tous isoform of BIN1 is not present at synaptic terminals and
only the neuronal-specific BIN1 is detected (Figure S1A). In rat
neurons cultured in vitro, we only detect the neuronal-specific
isoform 1 expression, whereas glial cells in culture do not ex-
press BIN1 protein (Figure S1B).
Neuronal BIN1 Levels Inversely Correlate with Tau
Pathology Propagation in a Mixed-Culture Assay
We previously developed two Tau pathology propagation in vitro
models (Calafate et al., 2015), which we used here to study a po-
tential role for BIN1 in Tau pathology propagation. The mixed-
culture assay consists of the co-culture of HEK293 persistently
harboring intracellular TauP301L-GFP aggregates (clone 2),
with rat hippocampal neurons expressing soluble hemagglutinin
(HA)-tagged TauP301L (HA-TauP301L) (Figure 1A). When clone
2 cells are co-cultured with rat neurons from day in vitro (DIV)
5–12, neuronal HA-TauP301L aggregation can be detected us-
ing an Alphalisa assay that specifically detects aggregation of
HA-tagged Tau expressed in neurons. Aggregation in the neu-
rons is used as a readout for Tau pathology propagation that oc-
curs as a consequence of Tau ‘‘seeds’’ present in the donor cell
‘‘clone 2,’’ followed by induction of soluble Tau aggregation in
the receiving neuronal cells (Figure 1B). To assess whether, in
this system, Tau pathology propagation leads to an increase in
neuronal damage, we co-cultured either HEK293 cells stably ex-
pressing soluble TauP301L-GFP (clone 1; where propagation
does not occur; Calafate et al., 2015) or clone 2 cells with neu-
rons expressing HA-tagged Tau. However, the number of py-
knotic nuclei measured by an increase in chromatin condensa-
tion and nuclear shrinkage is not different between neurons
incubated with either clone (Vieira et al., 2014; Figures S1D
and S1E). Consistent with this, changes in cell culture toxicity
were also undetectable (Figure S1F).
Using the mixed-culture assay, we modulated BIN1 levels in
the receiving neuronal cells. Lowering BIN1 levels by neuronal
transduction on DIV2 with BIN1 short hairpin RNA (shBIN1)
does not trigger neuronal toxicity (Figures 1C and 1C’) but
does result in increased Tau aggregation in these neurons, sug-
gesting that Tau pathology propagation is promoted (Figure 1D).
We next sought to assess whether increased neuronal BIN1
levels also interfered with Tau pathology propagation. Transduc-
tion of the receiving neuronal cells with the human neuronal iso-
form 1 (BIN1V1) on DIV2 (Figure S1C) results in decreased
neuronal Tau aggregation, indicating that neuronal BIN1 levels932 Cell Reports 17, 931–940, October 18, 2016and Tau pathology propagation are inversely correlated (Fig-
ure 1E). Indicating specificity, overexpression of BIN1V1 rescues
the increase in neuronal Tau aggregation triggered by shBIN1
that only targets the rat protein and not the expression of the hu-
man protein (Figure 1F). Importantly, expression in the rat neu-
rons of the human ubiquitous BIN1 isoform 9 (BIN1V9) that lacks
the CLAP domain (Figure S1C) has no effect on Tau pathology
propagation in the mixed culture assay (Figure S1G). The effects
we observe are also not the result of different Tau expression
levels, as indicated in Figures S1H–S1K. Together, these data
suggest a major role for neuronal-specific BIN1 isoforms in Tau
pathology propagation.
BIN1 Levels Inversely Correlate with Tau Pathology
Propagation in a Mini-circuit Assay
To further validate the inverse correlation between neuronal
BIN1 levels and Tau pathology propagation, we used a three-
chamber microfluidic system, where Tau pathology propagation
depends on the presence of inter-neuronal synaptic contacts
(Calafate et al., 2015). We cultured neurons for 15 days in three
isolated chambers (C1, C2, and C3) that are connected by
grooves through which only axons can project and form synap-
ses with the neurons in the adjacent chamber (Figures 1G and
1H). We transduced neurons in all three chambers with
TauP301L, but this Tau does not aggregate unless triggered.
Tau aggregation was triggered in C1 by adding pre-formed
Tau fibrils to the chamber, on DIV2. To counteract fibril diffusion
from C1 to adjacent C2 and C3, medium volumes in C2 and C3
are higher than in C1. The formation of aggregates of TauP301L
in adjacent chambers is used as a readout for Tau pathology
propagation. After lysis, TauP301L aggregation in C1, C2, and
C3was quantified by the TauP301L aggregate-specific Alphalisa
on DIV15 (Figure 1H). When neurons are present in all three
chambers, we observe TauP301L aggregates in C1, C2, and
C3. However, we previously showed that, when no neurons are
present in C2, adding pre-formed Tau fibrils to C1 does not
induce TauP301L aggregation in the neurons in C3, indicating
that the chambers are functionally isolated.
To assess the role of neuronal BIN1 in the propagation of Tau
pathology, we transduced the neurons in C2 and C3with shBIN1
to lower BIN1 levels. Consistently, we find that decreased BIN1
results in increased Tau aggregation levels in C2 and C3, indic-
ative of increased Tau pathology propagation from C1 to C2
and C3 (Figure 1I). Conversely, expressing BIN1V1-GFP in C2
and C3 causes decreased Tau pathology propagation (Fig-
ure 1J). Hence, BIN1 is a dosage-sensitive modulator of Tau
pathology propagation between synaptically connected neurons
in vitro.
Impaired Dynamin Activity Decreases Tau Pathology
Propagation
Neuronal BIN1 is thought to be involved in CME by interacting
with clathrin, AP2, and dynamin (McMahon et al., 1997; Micheva
et al., 1997). To further elucidate whether CME is a process
involved in Tau pathology propagation, we used pharmacolog-
ical inhibition of dynamin, a protein needed during CME (Fergu-
son et al., 2007). In cultured neurons, transferrin uptake, which is
mediated by CME, is decreased following treatment with 1 mMof
Figure 1. The Neuronal BIN1 Isoform In-
hibits Tau Pathology Propagation
(A) Confocal representative images of mixed-cul-
ture assay. Clone 2 cells with TauP301L-GFP ag-
gregates (green) were co-cultured at DIV5 with
hippocampal neurons expressing HA-TauP301L.
Cultures were fixed at DIV12 in 4% para-
formaldehyde (PFA) immuno-labeled for total HA-
TauP301L using HA antibody (red). DAPI, nuclei
(blue). The scale bar represents 50 mm.
(B) Schematic representation of Tau pathology
propagation assay in the mixed-culture assay.
(C) Western blot of hippocampal neurons
transduced with control shRNA or shRNA to BIN1
and probed with anti-BIN1 C99D antibody.
(C’) Neuronal toxicity measured using ToxiLight
BioAssay kit (Lonza) and normalized to control
shRNA conditions. n = 3 independent experi-
ments. t test; ns, not significant.
(D–F) Alphalisa results indicating aggregated Tau
levels in the following mixed-culture assay condi-
tions: neurons co-transduced with HA-TauP301L
and (D) control shRNA or shBIN1 (E) control
or BIN1V1 expression vector (F) shRNA com-
bined with control or BIN1V1 expression vector.
Clone 2 cells were co-cultured on DIV5. Lysates
were prepared and aggregated HA-TauP301L
measured by Alphalisa on DIV12. Error bars
represent SEM; n > 3 independent experiments.
Student’s t test; *p < 0.05; **p < 0.01; ***p < 0.001.
(G) Confocal representative images of hippocam-
pal neurons cultured in the three chambers (C1,
C2, and C3) of the microfluidic device fixed at
DIV15 in 4% PFA immuno-labeled with b-III-
tubulin antibody (white). DAPI: nuclei (blue). The
scale bar represents 20 mm.
(H) Schematic representation of Tau pathology
propagation assay in the microfluidic device.
(I and J) Neurons in the microfluidic device were
transduced in C1 with TauP301L and co-trans-
duced in C2 and C3 with TauP301L plus (I) control
shRNA or shBIN1 or (J) GFP (control) or BIN1V1-
GFP expression vector on DIV2. Pre-formed fibrils
were added to C1 in DIV5. Each channel was lysed
and aggregated TauP301L measured by Alphalisa
on DIV15. Error bars represent SEM; n > 3 inde-
pendent experiments. Student’s t test; *p < 0.05.
See also Figure S1.dynasore or 1 mM of the more specific Dynamin JNJ inhibitor
(Gordon et al., 2013; Figures 2A and 2B). Next, we used the
mixed-culture assay and treated cells with 0.3, 1, or 3 mM ofCell Reither dynamin inhibitor from DIV5 to
DIV12. We find that Tau pathology propa-
gation is significantly decreased when
using 1 mMor 3 mMof inhibitor (Figure 2C).
This treatment does not completely abro-
gate Tau pathology propagation, sug-
gesting that other routes are contributing
to this process (Kfoury et al., 2012; Wu
et al., 2013). The effect observed is not
because Tau levels in the neurons or inthe clone 2 cells change when adding the inhibitors nor because
of the inhibitors causing cellular toxicity within the assay period
(Figures S2A–S2D). Hence, whereas lower BIN1 levels causeeports 17, 931–940, October 18, 2016 933
Figure 2. Tau Pathology Propagation Decreases when Inhibiting Dynamin Activity
(A) Quantification of transferrin-TxRed (white) uptake in neurons DIV9 treated with 1 mM dynamin inhibitors. n = number of cells analyzed. Error bars represent
SEM; n > 3 independent experiments. ANOVA/Tukey’s; *p < 0.05; ****p < 0.0001.
(B) Confocal representative images of transferrin uptake (white). The scale bar represents 10 mm.
(C) Alphalisa to reveal aggregated Tau levels in neurons where dynamin is inhibited. Neurons were transduced with HA-TauP301L at DIV2. Clone 2 cells were co-
cultured on DIV5. Mixed cultures were treated with inhibitors from DIV5 to DIV12. Cultures were lysed and aggregated HA-TauP301L measured by Alphalisa on
DIV12. Error bars represent SEM; n > 3 independent experiments. ANOVA/Tukey’s; ns, not significant; *p < 0.05; ***p < 0.001; ****p < 0.0001.
See also Figure S2.increased propagation of Tau pathology, lower dynamin activity
results in decreased propagation of Tau pathology.
BIN1 Inhibits the Flux to Endosomes
To assess whether BIN1, similar to dynamin, also affects CME in
our neuronal system, we quantified transferrin uptake. When we
treat the neurons with short hairpin RNA (shRNA) to lower BIN1
levels, transferrin uptake is increased. Conversely, when we
overexpress BIN1V1, we observe much-less transferrin uptake
(Figures 3A and 3B). This effect is again specific to the neuronal
isoform because overexpression of BIN1V9 that lacks CLAP
domain does not affect transferrin uptake (Figures S3A andS3B).
Given that BIN1 interacts with dynamin (Wigge et al., 1997), we
tested the hypothesis that BIN1 affects CMEby sequestering dy-
namin. We transfected dynamin-GFP in neurons with decreased
levels of BIN1 or increased levels of BIN1V1. Whereas the num-
ber of dynamin-GFP puncta at the membrane does not change,
overexpression of BIN1V1 causes the size of the dynamin-GFP
puncta to increase (Figures 3C–3E). BIN1 is atypical in that
most proteins with BAR domains increase the dynamics ofmem-
brane curvature, whereas BIN1 was recently shown to decrease
membrane curvature dynamics as a consequence of very-tight
BAR-domain packing (Adam et al., 2015). Hence, we surmise
that the increased dynamin puncta size may be the result of
increased endocytic membrane rigidity, leading to sequestering
of dynamin-GFP at nascent vesicle necks, thereby interfering
with efficient CME (Figure 3K). Furthermore, our data also indi-
cate that lower BIN1 levels do not affect this step of CME.
To address whether BIN1 affects later stages of endosomal
trafficking, we expressed Rab5-GFP, an early endosome
marker, and quantified neuronal endosome number and mor-
phology. Neurons with lower levels of BIN1 harbor enlarged
Rab5-positive endosomes, consistent with the increased endo-
cytosis we observed. In contrast, BIN1V1 overexpression results934 Cell Reports 17, 931–940, October 18, 2016in a lower number of Rab5-GFP-positive endosomes, consistent
with decreased endocytosis in these cells (Figures 3F–3H).
Enlarged endosomes are a hallmark phenotype of activated
Rab5 that is localized to the endosomal membrane (GTP-loaded
active form). Using western blotting of crude membrane frac-
tions, we find a 50% increase in membrane-associated Rab5
in neurons with less BIN1 compared to controls with scrambled
shRNA and a 25% decrease in neurons overexpressing BIN1V1
(Figures 3I and 3J). Hence, BIN1V1 inhibits Rab5 activation and
endosome formation (Figure 3K).
Tau Seeds Hijack the Endocytic Route
To address the question whether CME is in part mediating
propagation of Tau pathology between cell populations, we
imaged TauP301L-GFP in our in vitro co-culture system using
immunolabeling of GFP. We first co-cultured clone 1 cells with
hippocampal neurons but did not observe TauP301L-GFP in
the neurons (Figure S4A). In contrast, when clone 2 cells
were co-cultured with hippocampal neurons, small amounts of
TauP301L-GFP originating from clone 2 cells were detected in
the neurons (Figures S4B and S4B’). Next, to further increase
detection efficiency, we also isolated Tau aggregates from clone
2 cells and labeled them with the fluorescent dye Dylight 488.
Cultured hippocampal neurons were pulsed with these aggre-
gates and with transferrin and were imaged 4 hr later. About
40% of the internalized aggregates co-localize with transferrin-
positive structures (Figures 4A and 4B), indicating these aggre-
gates internalized by CME. To determine whether Tau aggre-
gates travel to endosomes, we visualized intraluminal Tau
aggregate accumulation following expression of the constitu-
tively active GTP-bound Rab5, Rab5Q79L. This mutant freezes
the endocytic flux at the early endosome sorting station, leading
to increased fusion and enlargement of early endosomes. We
observe the accumulation of Tau aggregates inside Rab5Q79L
(legend on next page)
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endosomes in neurons (Figure 4C) and in other cell types within
24 hr (Figures S4C and S4D), indicating that Tau aggregates
enter neurons by CME and are trafficked to endosomes.
Tau Aggregates Damage Vesicle Membranes
An outstanding question that remains is how extracellular aggre-
gates can reach the cytosol after internalization, where they may
act as a template for the further induction of aggregation of sol-
uble Tau. We reasoned that Tau aggregates may damage endo-
somal membranes and used a galectin-3-binding assay. Galec-
tin-3 is a protein that binds to b-galactoside sugars that are
present on the cell surface and that are internalized into the
lumen of endocytic vesicles. Under normal conditions, b-galac-
toside sugars are not accessible to cytosolically expressed ga-
lectin-3, unless the endomembranes are leaky (Chen et al.,
2014; Freeman et al., 2013). We treated galectin-3-mCherry-ex-
pressing neurons with clone 2 Tau aggregates (labeled with
Dylight 488) and imaged galectin-3-mCherry localization (Fig-
ure 4D).Whereas non-treated cells show diffuse cytoplasmic ga-
lectin-3-mCherry, the treatment with Tau aggregates results in a
clear re-localization of galactin-3 from the cytoplasm to vesicular
structures, with a robust increase in the number and area of ga-
lectin-3-positive vesicles in both neuronal projections and in cell
bodies within 24 hr (Figures 4E and 4F). These results indicate
that the internalization of Tau aggregates induces rupture of
the vesicular endosomal membranes. Our work is consistent
with a model where at least some Tau aggregates take advan-
tage of an endocytic route, and like some pathogens, they
then are able to escape from such compartments into the cytosol
(Freeman et al., 2013; Rajendran et al., 2010).
DISCUSSION
Genome-wide association studies (GWASs) and other genome-
wide approaches have identified numerous new genetic risk fac-
tors for AD, but how they contribute to the mechanisms of pa-
thology has been challenging to resolve. In this work, we show
that BIN1, the protein encoded by the second-most-prevalent
LOAD susceptibility genetic locus, is a dosage-sensitivemodifier
of the propagation of Tau in synaptically connected neurons.
In our work, we took advantage of overexpression of the
pathogenic mutant TauP301L. In AD, wild-type Tau becomes
hyperphosphorylated and also participates in the pathological
cascade. Therefore, validation of our findings in models that
only depend on the endogenous Tau protein and the involvement
of endogenous Tau in the TauP301L propagation processFigure 3. BIN1 Inhibits Endocytic Flux
(A and B) Imaging and quantification of transferrin uptake in hippocampal neuron
vector on DIV2. DIV9 neurons were fixed in 4% PFA, and different conditions we
(C–E) Neurons treated as in (A) and (B) transfected with dynamin-GFP. (C) Num
represents 10 mm.
(F–H) Neurons treated as in (A) and (B) transfected with Rab5-GFP. (F) Number an
(I and J) Rab5 membrane association (a proxy for Rab5 activity) was quantified by
Rab5 (inactive) as measured in the cytosol (C) and membrane (M) fractions.
For all experiments: n, number of cells analyzed. Error bars represent SEM; n
**p < 0.01.
(K) Model of BIN1 action in the endocytic pathway; see text for details.
See also Figure S3.
936 Cell Reports 17, 931–940, October 18, 2016remain to be determined. However, it has previously been
described that removing endogenous Tau from mouse brain
does not halt the propagation of TauP301L (Wegmann et al.,
2015), indicating endogenous Tau is not strictly necessary.
In addition to previous findings that implicate macropinocyto-
sis and bulk endocytosis in the internalization of Tau aggregates
(Holmes et al., 2013; Wu et al., 2013), our work now suggests
also an important positive contribution for CME in the propaga-
tion of Tau pathology in the brain and also paves the way for
analyzing other AD risk factors, several of which are also con-
nected to the mechanisms of intracellular membrane trafficking.
BIN1 is a member of the BAR-domain-containing proteins that
have been shown to sense or inducemembrane curvature (Qual-
mann et al., 2011). The protein binds clathrin and AP2 and re-
cruits dynamin, indicating an involvement in endocytosis, but
the exact mode of action in neurons remained concealed.
Whereas the closest BIN1 homolog, amphiphysin1, has been
shown to play a positive role in endocytosis (Di Paolo et al.,
2002), we find that BIN1 slows down the process. We suggest
that increased levels of BIN1 confiscate dynamin, and together
with previous work, the data suggest that BIN1 senses coated-
pit curvature and may generate at the base of nascent vesicles
very rigid necks that sequester dynamin. When the levels of
BIN1 are lower, dynamin function is normal and vesicle formation
can proceed (Figure 3K).
Our work also shows that BIN1 is involved in a later endocytic
step during early endosome formation, a process that is regu-
lated by Rab5 activation. Consistently, decreased BIN1 levels
lead to over-activated Rab5 whereas increased BIN1V1 levels
result in the inactivation of Rab5. Rab5 over-activation, a condi-
tion that promotes endosome enlargement, is known to upregu-
late endocytosis and mediate endosomal fusion (Kim et al.,
2016; Stenmark et al., 1994). Interestingly, we find that exoge-
nous TauP301L aggregates are internalized and reside in
neuronal endosomes. In addition, endosomal trafficking has
been implicated in APP metabolism (Rajendran and Annaert,
2012), suggesting endosomal defects may affect both Ab and
Tau biology.
BIN1 and Rab5 are not thought to interact directly; however,
another GWAS risk factor, RIN3 (Karch and Goate, 2015), may
be the link: RIN3 has been described to share interactions with
both Rab5 and BIN1 (Kajiho et al., 2003, 2011). RIN3 stimulates
guanine nucleotide exchange on Rab5, thereby activating the
protein. Hence, an exciting scenario is that BIN1 and Rab5
compete for RIN3. Increased BIN1 levels do not only sequester
dynamin but also RIN3, thus preventing efficient Rab5 activation.s transduced with control shRNA or shBIN1 and control or BIN1V1-expressing
re analyzed by confocal microscopy. The scale bar represents 10 mm.
ber and (D) size of (E) dynamin-GFP puncta were quantified. The scale bar
d (G) size of (H) Rab5 puncta were quantified. The scale bar represents 10 mm.
western blot by the ratio of membrane-bound Rab5 (active) relative to cytosolic
> 3 independent experiments. Student’s t test; ns, not significant; *p < 0.05;
Figure 4. Tau Aggregates Hijack and Damage Endocytic Vesicles
(A–D) Tau aggregates extracted from clone2 cells, labeled with Dylight 488 (aggregates), were added to themedium of DIV9 neurons and followed under different
conditions. White arrows indicate co-localization. (A) Aggregates (green) were added for 4 hr and co-localization with transferrin-TxRed (red)-positive vesicles as
assessed. DAPI, nuclei (blue). The scale bar represents 20 mm. (B) Percentage of co-localization of aggregates with transferrin-TxRed-positive compartments is
(legend continued on next page)
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Conversely, lower BIN1 levels result in ‘‘more-free’’ RIN3 that ac-
tivates Rab5. Interestingly, AD brains were found to harbor
enlarged endosomes (Cataldo et al., 2008; Nixon, 2005) as well
as lower neuronal BIN1 levels (Holler et al., 2014), consistent
with our observations in our Tau pathology propagation models
as well.
Contrarily to our findings, a positive correlation between BIN1
and Tau-mediated toxicity was previously suggested (Chapuis
et al., 2013). In order to assess how altered BIN1 expression
would potentially be involved in AD pathogenesis, the authors
abolished the closest homolog to BIN1 inDrosophila, amphiphy-
sin (Amph). Loss of Amph rescued toxicity induced by Tau
expression in the fly eye. However, fly Amph does not contain
a CLAP domain that is present in BIN1 and has been shown to
interact with endocytic proteins. Drosophila amphiphysin is
mostly expressed in muscles, and the protein is also not involved
in endocytosis (Razzaq et al., 2001; Leventis et al., 2001; Zelhof
et al., 2001). Our work indicates that the neuronal isoform of
BIN1, implicated in AD pathology, contains the CLAP domain
and it is a negative regulator of endocytosis. Hence, fly Amph
andmammalian BIN1may act through different modes of action,
and it also remains to be seenwhether fly Amph has an impact on
the spreading of Tau pathology. Our work highlights that it is
important to consider BIN1 isoform and tissue-specific effects.
Our in vitro models suggest that Tau aggregates are being
transferred between two cell populations as substantiated by
our data showing that, in the mixed culture assay, aggregates
from clone 2 cells propagate to neurons. Moreover, our work
suggests a model where internalization of Tau aggregates oc-
curs at least in part through the endocytic route (not excluding
other entry routes as well), and once internalized, aggregates
are capable of disrupting vesicle membrane, escaping into the
cytosol. We suggest that the Tau aggregates that leaked into
the cytosol recruit soluble Tau from the ‘‘naı¨ve cell’’ into new ag-
gregates, thereby perpetuating pathology in closely connected
cells. However, these experiments do not exclude that another
signal or secondary messenger generated by Tau aggregation
in the donor cell diffuses to an acceptor cell to help in inducing
Tau aggregation. If such signals play a role in this process,
they would represent attractive therapeutic target to halt Tau pa-
thology propagation. Nonetheless, the many proteins encoded
by genes in AD GWAS lists that are involved in membrane traf-
ficking further underscore the importance of endocytosis in AD
pathology, not only in the production of Ab but, as we show
here, also in the propagation of Tau pathology.
EXPERIMENTAL PROCEDURES
Primary Cultures
Hippocampal neurons were cultured from embryonic day 17 (E17) to E18
Wistar rat embryos (Charles River Laboratories) and maintained as described
previously (Calafate et al., 2015). Viral transductions and Lipofectamine 2000shown. Error bars represent SEM; n > 3 independent experiments. (C) Aggregates
mCherry (red) and accumulate in these structures. DAPI, nuclei (blue). The scale b
hippocampal neurons expressing galectin-3-mCherry (red) and co-localize with
(E and F) Number and size of galectin-3-mCherry-positive vesicles from condition
of cells analyzed. Error bars represent SEM; n > 3 independent experiments. AN
See also Figure S4.
938 Cell Reports 17, 931–940, October 18, 2016(Invitrogen; 11668019) transfections were performed on DIV2 and DIV7,
respectively (see Supplemental Experimental Procedures). Cytotoxicity as-
says was performed using ToxiLight BioAssay Kit (Lonza) following the guide-
lines. For biochemistry analysis, cultures were lysed in 1% Triton lysis buffer.
Mixed Culture
Mixed-culture assays were performed as described in Calafate et al. (2015).
Briefly, clones 1 or 2 were co-cultured with hippocampal neurons from DIV5
to DIV12.
Microfluidic Chambers
Microfluidic devices (Xona Microfluidics) were placed on coated coverslips,
and 80,000 neurons were plated per channel. Transductions with plasmids
of interest (see Supplemental Experimental Procedures) were performed at
DIV2. Cultures were maintained at 37C and 5% CO2 up to 15 days.
Pre-formed Fibrils
The repeat domain from the longest human Tau isoform (K18; residues Q244-
E372) with a P301L mutation was aggregated as described before (Calafate
et al., 2015). Fibrils were added to culture medium in a final concentration of
50 nM.
Alphalisa Immunoassay
Alphalisa was set up to detect total Tau or specifically aggregated Tau. To
detect total Tau, components of capturing mixture (biotin/acceptor beads)
were conjugated with two different antibodies present in the Tau protein: for
HA-tagged Tau, an HA (Roche Life Science; 12CA5) and hT10 (in house)
and, for untagged total Tau, hT7 and hT10. To specifically detect aggregated
Tau, components of capturing mixture were conjugated to the same antibody:
for HA-tagged Tau, an HA (Roche Life Science; 12CA5) and, for untagged total
Tau, hT10. Reaction was performed as described before (Calafate et al., 2015).
Dynamin Inhibitors
Dynasore was acquired (Abcam; ab120192). A second dynamin inhibitor (Dy-
namin-JNJ) was synthetized in house as an analog of a second-generation
indole-based dynamin GTPase inhibitor (Gordon et al., 2013).
Isolating and Labeling Clone 2 Aggregates
Dissociated clone 2 cells were dounced 30 times in 0.05M sodium borate
buffer at pH 8.5 (on ice). To remove membranes, sample was spun at
5,000 3 g for 15 min. Supernatant was labeled for 1 hr at room temperature
with DyLight 488 NHS Ester (ThermoFisher; 46402) and dialyzed for 13 PBS
on a Slide-A-Lyzer Dialysis Cassettes (ThermoFisher; 66380).
Transferrin Assay
Transferrin Texas Red Conjugate (ThermoFisher; T2875) was added for 20min
to culture medium into a final concentration of 25 mg/mL.
Image Acquisition and Analysis
Images were captured on a Leica SP8 confocal microscope (Leica Microsys-
tems). Images were thresholded with FIJI software using constant settings.
Number of puncta was measured per length of dendrite of the neuron under
analysis. Only primary and secondary dendritics were included in the analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.09.063.(green) were added for 24 hr to hippocampal neurons expressing Rab5Q79L-
ar represents 20 mm. (D) Control buffer or aggregates were added for 24 hr to
these vesicles. DAPI, nuclei (blue). The scale bar represents 20 mm.
s in (D) were quantified in (E) neuronal projections and (F) cell bodies. n, number
OVA/Tukey’s; ****p < 0.0001.
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